Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression

Annals of Neurology

Volumn 57, Issue 1, 2005, Pages 34-41

  Shah, Khalid ^a   Bureau, Emilie ^a   Kim, Dong Eog ^a   Yang, Katherine ^a   Tang, Yi ^a   Weissleder, Ralph ^a   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; GLIOMA; IMAGE ANALYSIS; IMAGING SYSTEM; IN VIVO STUDY; MOUSE; NEURAL PRECURSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; STEM CELL; TREATMENT OUTCOME; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL COUNT; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CELL TRANSPLANTATION; CLONING, MOLECULAR; DIAGNOSTIC IMAGING; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALACTOSIDES; GLIOBLASTOMA; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; MUTAGENESIS; NEURONS; RECOMBINANT PROTEINS; STEM CELLS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11144231673     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20306     Document Type: Article

References (28)

1. Stiles CD. Cancer of the central nervous system. Review of an AACR special conference in cancer research with the joint section on tumors of the AANS/CNS (San Diego, CA, June 7-11, 1997). Biochim Biophys Acta 1998;1377:R1-R10.
2. Chiocca EA, Aghi M, Fulci G. Viral therapy for glioblastoma. Cancer J 2003;9:167-179.
3. Snyder EY, Macklis JD. Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neuro-degenerative conditions. Clin Neurosci 1995;3:310-316.
4. Ourednik J, Ourednik V, Lynch WP, et al. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 2002;20:1103-1110.
5. Gage FH. Mammalian neural stem cells. Science 2000;287: 1433-1438.
6. Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003;22:6865-6872.
7. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
8. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
9. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo21/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001;7:1362-1369.
10. Norris JS, Hyer ML, Voelkel-Johnson C, et al. The use of Fas ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther 2001;1:123-136.
11. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-260.
12. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
13. Shah K, Tung CH, Yang K, et al. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 2004;64:3236-3242.
14. Ryder EF, Snyder EY, Cepko CL. Establishment and characterization of multipotent neural cell lines using retrovirus vector-mediated oncogene transfer. J Neurobiol 1990;21:356-375.
15. Tang Y, Shah K, Messerli SM, et al. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther 2003;14:1247-1254.
16. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56:5079-5086.
17. Ichikawa T, Hogemann D, Saeki Y, et al. MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 2002;4:523-530.
18. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59: 6153-6158.
19. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-8633.
20. Xiao C, Yang BF, Asadi N, et al. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002;277:25020-25025.
21. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2:148-164.
22. Hao C, Beguinot F, Condorelli G, et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 2001;61:1162-1170.
23. Roth W, Isenmann S, Naumann U, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999;265:479-483.
24. Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002;4:312-323.
25. Naumann U, Waltereit R, Schulz JB, Weller M. Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. J Neurooncol 2003;61: 7-15.
26. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Nad Acad Sci USA 2000;97: 12846-12851.
27. Wu X, He Y, Falo LD, Hui KM, Huang L. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. Mol Ther 2001;3:368-374.
28. Isacson O, Breakefield XO. Benefits and risks of hosting animal cells in the human brain. Nat Med 1997;3:964-969.